Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine
Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options.
Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the
‘reduction of mild to moderate recurrent lameness associated with
non-septic joint inflammation in horses’.
Equine lameness is truly common and impacts horse performance as well as
equine welfare1. Current treatment is not satisfactory for
all cases and there is a clear need for innovation and new treatment
options. Hence, the significant interest in treatment beyond symptoms,
namely combatting the underlying root cause.
Arti-Cell® Forte is a groundbreaking first-ever approved therapy,
developed towards targeting lameness, utilising specifically primed,
chondrogenic induced stem cells. Arti-Cell® Forte comes in an ultra-low
frozen ready-to-use presentation.
Boehringer Ingelheim and Global Stem cell Technology (GST), that formed
a partnership last year, have the same ambition to bring new treatments
and solutions to improve animal health; therefore, Arti-Cell® Forte was
specifically designed for horses to provide a convenient and long-term2
solution for recurrent lameness.
“A quarter of the entire equine population1 develops
osteoarthritis at some point in their life. Priming the cells towards
cartilage aids them to deliver the right activities in the affected
joint,” says Jan Spaas, CEO of GST. “We are absolutely delighted with
our first marketing authorisation from the European Commission and the
first stem cell-based product in Animal Health. We are sure that with
our partner Boehringer Ingelheim this product will become a game changer
in equine health.”
Dr. Erich Schoett, Head of the Global Strategic Business Unit Equine at
Boehringer Ingelheim, shares: “We are proud to continue to set new
standards of care for horses to optimise their health and well-being in
partnership with veterinarians. Early disease detection and early
treatment are key to ensure that horses are healthy and live longer,
happier lives. Arti-Cell® Forte as the first-ever approved stem
cell-based product offers to veterinarians and horse owners a
ready-to-use solution to help raising the health and quality of life for
horses with mild to moderate recurrent lameness”.
Following the scientific review by the European Medicines Agency2
and decision of EU marketing authorisation by the European Commission,
Arti-Cell® Forte is now approved as a veterinary medicine for the
treatment of equine lameness. It will be available from May and June
2019 onwards in a range of European Countries.
Intended audiences
This press release is issued from our Corporate Headquarters in
Ingelheim, Germany and is intended to provide information about our
global business. Please be aware that information relating to the
approval status and labels of approved products may vary from country to
country, and a country-specific press release on this topic may have
been issued in the countries where we do business.
Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/arti-cell-forte-stem-cell-based-veterinary-product
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005445/en/